Therapeutics

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

From long‑acting ART to vaccines and curative treatments, innovation is accelerating. Explore ICON’s new HIV whitepaper for insights on breakthrough therapies, including twice-yearly injectable PrEP, vaccines, and curati...

Integrating modern technologies and careful preparation can contribute significantly to supporting and enhancing the performance of the people who make cardiovascular outcome trials function. Read the article for human-c...

Successful execution of a cardiovascular outcome trial depends on patient retention — but there are other areas of a CVOT where considering the human element is crucial as well. Explore how people impact multiple dimensi...

While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit...

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...

The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series...

Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered...

For the third and final blog in our series, we discuss ISO 10993-1 in the context of risk estimation. This blog looks at the upcoming revision of ISO 10993-1, which has sparked debate but now is in its final draft stag...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

Attending #ASH25? Stop by booth \#2161 to meet the ICON team and discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research ...

Meet ICON’s experts at #ASH25, booth \#2161 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https:...